2. Head and Neck

2.1.Clinical Trial
- 2.1.1.Nasopharyngeal Carcinoma (NPC)
- 2.1.2.Head and neck squamous cell carcinoma (HNSCC)
  - 2.1.2.1.HNSCC + Other Tumour Types
2.2. Supportive Cancer Care
2.3. Translational Research
2.4. Basic Research

2.0 Head and Neck
2.1 Clinical Trial
2.1.1 Nasopharyngeal Carcinoma (NPC)
Metastatic / Recurrent / Unresectable
Specific Selection Criteria: EBV Positive
Second-line to Fourth-line treatment: Phase 1b/2		Targeted Therapy (HDAC Inhibitor), Anti-Viral
An Open-Label, Multicenter Phase 1b/2 Study of Nanatinostat and Valganciclovir in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and in Combination with pembrolizumab in Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma.	Key Inclusion Criteria: Histologically or cytologically documented EBV+ tumor cells by EBER-ISH or LMP-1 per an archival tumor sample taken within 2 years prior to screening, otherwise a de novo biopsy is required. Patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) (excluding patients in the Phase 1b exploratory proof-of-concept cohort) for whom no potentially curative options are available, who have received at least 1 prior line of platinum-based chemotherapy and no more than 3 prior lines of therapy.	Nanatinostat (Histone Deacetylase (HDAC) Inhibitor) + Valganciclovir (Anti-Viral)	Dr. Victor Lee	Department of Clinical Oncology	vhflee@hku.hk	Angela IU 2255 5124

2.0 Head and Neck
2.2 Supportive Cancer Care
Early & Advanced Stage
Study Title	Main Inclusion/Exclusion	Principal Investigator	Department	Email	Contact number
Develop a digital selfcare coaching program (Digi-Coach) for newly-diagnosed head-and-neck cancer patients and caregivers on managing radiation side-effects and psychosocial needs: A Participatory action research study.	Key Inclusion Criteria: Patients Able to read and speak Cantonese or Mandarin fluently A new, primary diagnosis of stage I – IVA esophageal cancer; stage I – IV A/B (tongue, gum, oral cavity, nasopharynx, oropharynx, hypopharynx, parotid, or larynx) Waiting to receive a full course of curative-intent radiation therapy ≥60Gy with or without chemotherapy A Karnofsky performance score ≥ 70 and Access to a mobile device connected to the Internet to download the Digi-Coach patient version. Caregivers Family member identified by a recruited patient. Able to read and speak Cantonese or Mandarin fluently. Mentally and physically fit to perform caregiving tasks. Access to a mobile device connected to the Internet to download the Digi-Coach caregiver version. Key Exclusion Criteria: Patients Significant neurological or psychiatric disease. Caregivers Significant neurological or psychiatric disease.	Dr. Tongyao Wang	School of Nursing	tongyao1@hku.hk	3910 2790

2.0 Head and Neck
2.3.1 Translational Research
Study Title	Main Inclusion/Exclusion	Principal Investigator	Department	Email	Contact number
Tumor-Specific Alternative Splicing: A New Source for Neoantigens in Nasopharyngeal Carcinoma?	Key Inclusion Criteria: Prospective study; paired blood and tumor biopsies from 20 NPC patients obtained before treatment.	Wei Dai	Department of Clinical Oncology	weidai2@hku.hk	3917 6930
2.3.2 Translational Research
An Epigenetic Landscape Study: Unraveling the Role of Loss of CCCTC-binding Factor CTCF in Epigenetic Dysregulation in Epstein-Barr Virus-positive Nasopharyngeal Carcinoma.	Key Inclusion Criteria: Prospective study; 10 pairs of normal-primary NPC clinical specimens obtained before treatment.	Wei Dai	Department of Clinical Oncology	weidai2@hku.hk	3917 6930
2.3.3 Translational Research
Multi-Omics Integrative Analysis and Translational Study for Classification of Radiotherapy Sensitivity in Nasopharyngeal Carcinoma.	Key Inclusion Criteria: Retrospective study; late-stage NPC patients received standard treatment in Hong Kong and San-Yet Sen University Cancer Hospital with 5-year clinical follow-up data.	Wei Dai	Department of Clinical Oncology	weidai2@hku.hk	3917 6930
2.3.4 Translational Research
A Multi-Centre Translational Study for the Prognostic Biomarkers in NPC	Key Inclusion Criteria: Retrospective study; stage, gender and treatment matched NPC patients with and without de novo metastasis/local regional recurrence after 5 years follow up.	Wei Dai	Department of Clinical Oncology	weidai2@hku.hk	3917 6930
2.3.5 Translational Research
Understanding NPC Molecular Subtypes Associated with Clinical Outcome and Their Impact on Tumor Microenvironment	Key Inclusion Criteria: Retrospective study; stage matched NPC patients with or without metastasis/relapse after 5 years of treatment.	Wei Dai	Department of Clinical Oncology	weidai2@hku.hk	3917 6930
2.3.6 Translational Research
A study on Epstein-Barr Virus-associated immunosuppression using single-cell multi-omics spatial analysis	Key Inclusion Criteria: Retrospective study; stage and gender matched NPC patients with or without de novo metastasis after 5 years follow up.	Wei Dai	Department of Clinical Oncology	weidai2@hku.hk	3917 6930
2.0 Head and Neck
2.4.1 Basic Research
Study Title		Principal Investigator	Department	Email	Contact number
Pathogenicity of EBV isolated from nasopharyngeal carcinoma		Dr Lydia Wai Ting Cheung	School of Biomedical Sciences	lydiacwt@hku.hk	Dr Lydia Wai Ting Cheung 3917 6908
2.4.2 Basic Research
DNA Nanorobots for Precision Nasopharyngeal Carcinoma Therapeutics (CRF)		Prof. Julian Alexander Tanner	School of Biomedical Sciences	jatanner@hku.hk	Prof. Julian Alexander Tanner 3917 9472
2.4.3 Basic Research
Epidemiology of head and neck cancer		Dr. C.L. Cheung	Department of Pharmacology and Pharmacy	lung1212@hku.hk	3917 9462
2.4.4 Basic Research
Low-irradiance red light-triggered drug release for the treatment of retinoblastoma.		Dr. W.P. Wang	Department of Pharmacology and Pharmacy	wangwp@hku.hk	3917 9129

Cancer Research in HKUMed2. Head and Neck

Cancer Research in HKUMed
2. Head and Neck